CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Nivolumab 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02829918
NCT02829918Phase 2Completed
CompareCT.gov

A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Jul 12, 2016·Updated Mar 11, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab for Biliary Tract Cancer and Biliary Tract Neoplasms. Completed, enrolled 54 participants across 3 sites.

Detailed Summary

This research study is designed to see if a drug called Nivolumab is effective in treating patients with advanced refractory biliary tract cancers. Nivolumab has been approved by the U.S. Food and Drug Administration (FDA) for treatment of certain types of cancer but is not approved by the FDA for treatment of your type of cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer, Biliary Tract Neoplasms
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 12, 2016
Enrollment StartOct 5, 2016
Primary CompletionMar 27, 2019
Study CompletionMay 24, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.0 years ago

Interventions

Nivolumabdrug

Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.